233 related articles for article (PubMed ID: 32343676)
21. Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis.
Takayama K; Kaneshiro K; Tsutsumi S; Horie-Inoue K; Ikeda K; Urano T; Ijichi N; Ouchi Y; Shirahige K; Aburatani H; Inoue S
Oncogene; 2007 Jun; 26(30):4453-63. PubMed ID: 17297473
[TBL] [Abstract][Full Text] [Related]
22. Targeting the unique methylation pattern of androgen receptor (AR) promoter in prostate stem/progenitor cells with 5-aza-2'-deoxycytidine (5-AZA) leads to suppressed prostate tumorigenesis.
Tian J; Lee SO; Liang L; Luo J; Huang CK; Li L; Niu Y; Chang C
J Biol Chem; 2012 Nov; 287(47):39954-66. PubMed ID: 23012352
[TBL] [Abstract][Full Text] [Related]
23. Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies.
Chan SC; Selth LA; Li Y; Nyquist MD; Miao L; Bradner JE; Raj GV; Tilley WD; Dehm SM
Nucleic Acids Res; 2015 Jul; 43(12):5880-97. PubMed ID: 25908785
[TBL] [Abstract][Full Text] [Related]
24. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions.
Decker KF; Zheng D; He Y; Bowman T; Edwards JR; Jia L
Nucleic Acids Res; 2012 Nov; 40(21):10765-79. PubMed ID: 23019221
[TBL] [Abstract][Full Text] [Related]
25. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
[TBL] [Abstract][Full Text] [Related]
26. BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion.
Blee AM; Liu S; Wang L; Huang H
Oncotarget; 2016 Jun; 7(25):38319-38332. PubMed ID: 27223260
[TBL] [Abstract][Full Text] [Related]
27. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.
Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV
Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196
[TBL] [Abstract][Full Text] [Related]
28. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis.
Barros-Silva D; Costa-Pinheiro P; Duarte H; Sousa EJ; Evangelista AF; Graça I; Carneiro I; Martins AT; Oliveira J; Carvalho AL; Marques MM; Henrique R; Jerónimo C
Cell Death Dis; 2018 Feb; 9(2):167. PubMed ID: 29415999
[TBL] [Abstract][Full Text] [Related]
30. Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner.
Tam KJ; Dalal K; Hsing M; Cheng CW; Khosravi S; Yenki P; Tse C; Peacock JW; Sharma A; Chiang YT; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
Oncotarget; 2017 Feb; 8(6):9617-9633. PubMed ID: 28038451
[TBL] [Abstract][Full Text] [Related]
31. Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells.
Takayama K; Tsutsumi S; Katayama S; Okayama T; Horie-Inoue K; Ikeda K; Urano T; Kawazu C; Hasegawa A; Ikeo K; Gojyobori T; Ouchi Y; Hayashizaki Y; Aburatani H; Inoue S
Oncogene; 2011 Feb; 30(5):619-30. PubMed ID: 20890304
[TBL] [Abstract][Full Text] [Related]
32. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
[TBL] [Abstract][Full Text] [Related]
33. Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer.
Thangapazham R; Saenz F; Katta S; Mohamed AA; Tan SH; Petrovics G; Srivastava S; Dobi A
BMC Cancer; 2014 Jan; 14():16. PubMed ID: 24418414
[TBL] [Abstract][Full Text] [Related]
34. Long-range activation of FKBP51 transcription by the androgen receptor via distal intronic enhancers.
Makkonen H; Kauhanen M; Paakinaho V; Jääskeläinen T; Palvimo JJ
Nucleic Acids Res; 2009 Jul; 37(12):4135-48. PubMed ID: 19433513
[TBL] [Abstract][Full Text] [Related]
35. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms.
Koh CM; Iwata T; Zheng Q; Bethel C; Yegnasubramanian S; De Marzo AM
Oncotarget; 2011 Sep; 2(9):669-83. PubMed ID: 21941025
[TBL] [Abstract][Full Text] [Related]
36. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
[TBL] [Abstract][Full Text] [Related]
37. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM.
Kong D; Heath E; Chen W; Cher ML; Powell I; Heilbrun L; Li Y; Ali S; Sethi S; Hassan O; Hwang C; Gupta N; Chitale D; Sakr WA; Menon M; Sarkar FH
PLoS One; 2012; 7(3):e33729. PubMed ID: 22442719
[TBL] [Abstract][Full Text] [Related]
38. CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.
Augello MA; Liu D; Deonarine LD; Robinson BD; Huang D; Stelloo S; Blattner M; Doane AS; Wong EWP; Chen Y; Rubin MA; Beltran H; Elemento O; Bergman AM; Zwart W; Sboner A; Dephoure N; Barbieri CE
Cancer Cell; 2019 Apr; 35(4):603-617.e8. PubMed ID: 30930119
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer reactivates developmental epigenomic programs during metastatic progression.
Pomerantz MM; Qiu X; Zhu Y; Takeda DY; Pan W; Baca SC; Gusev A; Korthauer KD; Severson TM; Ha G; Viswanathan SR; Seo JH; Nguyen HM; Zhang B; Pasaniuc B; Giambartolomei C; Alaiwi SA; Bell CA; O'Connor EP; Chabot MS; Stillman DR; Lis R; Font-Tello A; Li L; Cejas P; Bergman AM; Sanders J; van der Poel HG; Gayther SA; Lawrenson K; Fonseca MAS; Reddy J; Corona RI; Martovetsky G; Egan B; Choueiri T; Ellis L; Garraway IP; Lee GM; Corey E; Long HW; Zwart W; Freedman ML
Nat Genet; 2020 Aug; 52(8):790-799. PubMed ID: 32690948
[TBL] [Abstract][Full Text] [Related]
40. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
